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Abstracts / Urological Science 26 (2015) S26eS35 S33Purpose:Mitochondria are the powerhouses of cells. Mitochondrial C-Raf is
a potential cancer therapeutic target, as it regulates mitochondrial function
and is localized to themitochondria by its N-terminal domain. However, Raf
inhibitor monotherapy induced S338 phosphorylation of C-Raf (pC-RafS338)
and impede therapy which is urged to be overcome in clinical practice.
Materials and Methods: We analyzed the growth-inhibition effect of Sor-
afenib and GW5074 combination therapy on multiple normal and cancer
cell lines by MTT assay in vitro and its anticancer effect with xenograft and
orthotopic metastasis animal models in vivo. The molecular mechanisms
involved in the regulation of mitochondrial function have been investigated
by means of western blotting analysis, fractionation, immunoprecipitation
assays and FACS analysis. The protein expression in cancer tissues and
normal counterparts was examined by immunohistochemistry assay.
Results: This study identiﬁed the interaction of C-Raf with S308 phosphor-
ylated DAPK (pDAPKS308), which together became co-localized in the mito-
chondria to facilitate mitochondrial remodelling. Combined use of the Raf
inhibitors sorafenib and GW5074 had synergistic anti-cancer effects in vitro
and in vivo, but targeted mitochondrial function, rather than the canonical
Raf signaling pathway. C-Raf depletion in knock-out MEFC-Raf-/- or siRNA
knock-down ACHN renal cancer cells abrogated the cytotoxicity of combi-
nation therapy. Crystal structure simulation showed that GW5074 bound to
C-Raf and induced a C-Raf conformational change that enhanced sorafenib
binding afﬁnity. In the presence of pDAPKS308, this drug-target interaction
compromised themitochondrial targetingeffect of theN-terminal domain of
C-Raf, which induced two-hit damages to cancer cells. First, combination
therapy facilitated pC-RafS338 and pDAPKS308 translocation from mitochon-
dria to cytoplasm, leading tomitochondrial dysfunction and ROS generation.
Second, ROS facilitated PP2A-mediated de-phosphorylation of pDAPKS308 to
DAPK. PP2A then dissociated from the C-Raf-DAPK complex and induced
profound cancer cell death. Increased pDAPKS308 modiﬁcation was also
observed in renal cancer tissues, which correlated with poor disease-free
survival and poor overall survival in renal cancer patients.
Conclusions: Besides mediating the anti-cancer effect, pDAPKS308 may
serve as a predictive biomarker for Raf inhibitors combination therapy,
suggesting an ideal pre-clinical model that is worthy of clinical translation.
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Purpose: Docetaxel-based chemotherapy has generally been considered
as one of the effective treatments for prostate cancer. Unfortunately,
clinical treatment with docetaxel often encounters a number of undesir-
able side effects, including drug resistance. Therefore, it has become
essential to identify molecular events that may be associated with the
development of docetaxel resistance. Tubulin isoforms have been previ-
ously examined for their resistant ability to docetaxel in many cancers, but
their real mechanisms remained unclear. In this study, we evaluated the
feasibility of employing docetaxel as a cytotoxic agent for PC3 cells and to
examine the role of acetyl-tubulin in docetaxel-resistant prostate cancer.
MaterialsandMethods:Aseries ofdocetaxel-resistant PC/DXcell subclones,
were established by chronically exposing PC3 to progressively increased
concentrations of docetaxel. Herein, we characterized the docetaxel-medi-
ated cytoxicity and molecular events in PC3 and PC/DX cells by MTT assay,
Western blotting, RT-PCR, real-time PCR and ﬂow cytometry analysis.
Results: Our results showed that levels of acetyl-tubulin, a-tubulin, b-
tubulin, g-tubulin, and bIII-tubulin were signiﬁcantly higher expression in
PC/DX25 than in parental PC3 cells byWestern blotting analysis. PC/DXwith
greater resistance to docetaxel had higher levels of acetyl-tubulin andMCAK
(mitotic centromere associate kinesin) than in PC3 cells. The expression ofacetyl-tubulin and MCAK was gradually increased by docetaxel in a dose-
and time-dependent manner in PC3 cells. Histone deacetylase 6, a deacetyl
enzyme of tubulin, mRNA and protein levels were signiﬁcantly decreased in
PC/DX25 than in PC3 cells. PC3 increased the chemoresistant ability to
docetaxel by HDAC6 knockdown and Tubastain A (HDAC6 inhibitor),
respectively. Conversely, PC/DX25 reversed the sensitivity to docetaxel by
MCAK knockdown. Notably, MCAK knockdown in PC/DX25 induced cell
cycle G2/M phase arrest after docetaxel treatment by ﬂow cytometry anal-
ysis. Overexpression of Plk1 in PC3 increased the cell survival rate and
resistance to docetaxel. Interestingly, we also found an evident up-regula-
tion of acetyl-tubulin protein expression after recombinant epidermal
growth factor treatment in a time-dependent manner in PC3 cells.
Conclusion: Up-regulation of acetyl-tubulin may play an important role in
docetaxel-resistant prostate cancer.
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Purpose: Urothelial carcinoma (UC) originating from bladder (UBUC) and
upper urinary tract (UTUC) is the most common tumor type of urinary
tract. However, its pathogenesis remains obscured. Through data mining
from a published transcriptomic database of UBUCs (GSE31684), we
identiﬁed SULF1 as the most signiﬁcant gene showing upregulation from
early tumor development to progression among those associated with
growth factor activity (GO:0030201). Sulfatase-1 (SULF1), encoded by
SULF1, is an extracellular 6-O-endosulfatase, which selectively removed 6-
O-Sulfate from heparan sulfate proteoglycans (HSPGs), involving in mul-
tiple biologic processes including tumorigenesis and cancer progression
proven in various cancers. However, the signiﬁcance of SULF1 expression
has never been evaluated in UC. We therefore analyze its signiﬁcance in
our well-characterized cohort of UC.
Materials and Methods: Quantigene assay was used to detect SULF1
messenger RNA (mRNA) level in 36 UTUCs and 30 UBUCs. Immunohisto-
chemistry evaluated by H-score was used to determine SULF1 protein
expression in 296 UBUCs and 340 UTUCs. We then correlated protein
expression status with clinicopathological features and evaluated the
prognostic signiﬁcance of SULF1 protein expression for disease-speciﬁc
survival (DSS) and metastasis-free survival (MeFS).
Results: Increments of SULF1 transcript level were associated with higher
pT status in both UTUC and UBUC (all P < 0.05). SULF1 protein over-
expression was signiﬁcantly associated with advanced primary tumor and
nodal statuses, and presence of vascular invasion in both groups of UC.
SULF1 overexpression not only predicted worse DSS and MeFS by univar-
iate analysis, but implied inferior DSS (UTUC, P < 0.001; UBUC, P ¼ 0.011)
and MeFS (UTUC, P < 0.001; UBUC, P ¼ 0.021) in multivariate analysis.
Conclusion: SULF1 overexpression is associated with advanced tumor
status and implicated adverse clinical outcome for both patients of UTUC
and UBUC. Our study unveiled the important role of SULF1 expression in
tumor progression in UC and may serve as a potential prognostic
biomarker and a novel therapeutic target of UC.
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